Late-Stage Sulfoximidation of Electron-Rich Arenes by Photoredox Catalysis

Scientific Literature


The sulfoximine group has been reported as a versatile and beneficial functionality for pharmaceutical or agrochemical entities. Herein, we report the Csp2–H sulfoximidation of electron-rich arenes ­under the irradiation of blue light using an organic acridinium photocatalyst and molecular oxygen or peroxodisulfates as terminal oxidants. The method allows for the late-stage introduction of various sulfoximines onto complex bioactive compounds showing high functional group compatibility without the need for prefunctionalization.

Authors: Henriette Lämmermann, Alexander Sudau, Daniel Rackl, Hilmar Weinmann, Karl Collins, Lars Wortmann, Lisa Candish, Daniel T. Hog*, Robin Meier*



Hepatochem offers a variety of photochemistry reactors and accessories that are used throughout the world to explore chemical conditions. All of our reactors are compatible with most vial formats and stirring plates. We also offer several photochemistry screening kits for calibration and accuracy.

Contact Us!

Interested in learning more about our products?
Complete our short contact form and we'll get back to you as soon as possible.

Photochemistry Starter Bundle

Our Photochemistry Starter Bundle includes everything you need to further explore the opportunities inherent with photochemical reactions. The Starter Bundle includes our standard photoreactor, two LED light sources, two vial holders, four sample reactions and UV safety glasses.

The Biomimetic Advantage

While microsomes have proven valuable as a predictive tool, their productive capabilities are limited. Biomimetic Chemistry, on the other hand, possesses the advantages of both chemistry and biology and is thus a much more efficient tool for metabolite synthesis.

See our Side By Side Comparison Chart Here

Metabolite Synthesis

Through our revolutionary technology, HepatoChem enables cost effective testable quantities of metabolites in-house even at the earliest stages of drug discovery. This new capability, which enables affordable early metabolite toxicity testing, offers drug companies the opportunity to save millions each year through dramatically improved drug pipelines.